AstraZeneca views $2B+ Fusion buyout as ‘starting point’ for better radiopharmaceuticals, combos
19 Mar 2024
AcquisitionRadiation Therapy
As the fifth major pharma player to stake a claim in radiopharmaceuticals, AstraZeneca sees big potential in improving on current options and exploring combination cancer therapies through its
$2 billion acquisition
of Fusion Pharmaceuticals.
Fusion’s lead program, a potential prostate cancer therapy, is expected to enter pivotal trials in the next year or two, according to Susan Galbraith, AstraZeneca’s head of oncology R&D. But the deal was also done with a broader ambition to tap into what she sees as an “exciting modality opportunity for cancer therapy,” particularly given the manufacturing capability the new subsidiary brings. It’s also a bet on the specific type of radioisotopes that Fusion works with.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.